Newron Pharmaceuticals S.p.A. (SWX:NWRN)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
18.28
-0.24 (-1.30%)
Dec 5, 2025, 5:30 PM CET
140.53%
Market Cap 364.89M
Revenue (ttm) 55.93M
Net Income (ttm) 23.65M
Shares Out 19.96M
EPS (ttm) 1.11
PE Ratio 16.44
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 49,370
Average Volume 115,554
Open 18.58
Previous Close 18.52
Day's Range 18.10 - 18.70
52-Week Range 5.20 - 19.72
Beta 0.68
RSI 66.40
Earnings Date Dec 18, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 22
Stock Exchange SIX Swiss Exchange
Ticker Symbol NWRN
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements